Cyclin D3 antibody (C-Term)
Quick Overview for Cyclin D3 antibody (C-Term) (ABIN1881178)
Target
See all Cyclin D3 (CCND3) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 252-281, C-Term
-
Predicted Reactivity
- B
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This CCND3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 252-281 amino acids from the C-terminal region of human CCND3.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- WB: 1:1000. WB: 1:1000. IHC-P: 1:100
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Expiry Date
- 6 months
-
-
- Cyclin D3 (CCND3)
-
Alternative Name
- CCND3
-
Background
- Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
-
Molecular Weight
- 32520
-
NCBI Accession
- NP_001129489, NP_001129597, NP_001129598, NP_001751
-
UniProt
- P30281
-
Pathways
- Cell Division Cycle, Mitotic G1-G1/S Phases, Glycosaminoglycan Metabolic Process
Target
-